Research Leaders
ICDC Research Leaders
Scott Klarenbach , MD, MSc, FRCPC
Phase 1 Leader
Dr. Scott Klarenbach is an Associate Professor in the Department of Medicine, Division of Nephrology at the University of Alberta in Edmonton; a Fellow at the Institute of Health Economics, and the Medical Director of Home Hemodialysis, Northern Alberta Renal Program.
Dr. Klarenbach is a nephrologist and has an MSc in Health Economics from the University of York, in the United Kingdom. Dr. Klarenbach investigates the economic impact of chronic kidney disease management to determine how health care resources can be used more effectively for patients. He has performed several economic evaluations, has been involved in several randomized trials, and collaborated on several systematic reviews.
Kathryn King-Shier, PhD
Phase 2 Leader
Dr. Kathryn King-Shier is a cardiovascular nurse scientist with expertise conducting qualitative research in vulnerable populations. She has led several interdisciplinary research teams and has the experience and knowledge to guide the researchers and decision-makers in Phase 2, including those from AHW and the CDM programs.
Dr. King-Shier is a professor in the Faculty of Nursing and in the Faculty of Medicine’s Department of Community Health Sciences at the University of Calgary.
Ross Tsuyuki, Pharm D, MSc, BSc (Pharm)
Phase 3 Leader
Dr. Ross Tsuyuki is a Professor of Medicine and pharmacist with expertise in clinical trials and health services research. Dr. Tsuyuki is Director of the Epidemiology Coordinating and Research (EPICORE) Centre, a health research coordinating centre which serves over 150 investigators and the Centre for COMmunity Pharmacy Research and Interdisciplinary Strategies (COMPRIS). He has completed several randomized trials examining the role and effectiveness of alternate health care providers and will spearhead the trial examining the impact of pharmacist prescribing within Phase 3.
